Transparency Market Research has created a database of market assessment reports on the global pharmaceutical industry. One valuable addition to this database is the new report, titled “Community Acquired Pneumonia (CAP) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.” The report tackles one of the more serious issues that the medical industry is currently handling. Nearly 4 to 5 mn people are being diagnosed with community acquired pneumonia every year around the world. Within those affected, at least 25% are usually in need of core medical attention and hospitalization. As such, CAP is a matter that the pharmaceutical industry should focus on in the coming years.
Get Free Sample Research Report:
Community acquired pneumonia implies any of the lung diseases categorized under it, only in this case, the person who acquires it has little to no access to any healthcare facility. CAP is known as the most common sickness across the world and also the one that leads to the most deaths. The standard treatment of CAP includes hospitalization for a brief period, wherein the patient is administered with cough medicine, antipyretics, and antibiotics. It differs from hospital acquired pneumonia, which afflicts a patient already inside a healthcare facility or who has visited one recently. Most doctors advice prevention to be the best form of cure in the case of CAP, which involves avoiding tobacco and taking the proper vaccines.
The global community acquired pneumonia market can be segmented on the basis of diagnosis type, treatment, and geography.
On the basis of diagnosis type, this market is segmented into laboratory testing and chest radiography. Of these, the former contains multiple sub-segments, including urine testing, sputum testing, blood cultures, ferritin levels, and pneumococcal antigen testing.
On the basis of treatment, the global CAP market is segmented into antiviral therapies and antibiotic therapies. The most common types of antiviral therapies include Acyclovir, Oseltamivir, and Ribavirin. A large number of antibiotic therapies are present in the global CAP market, including Levofloxacin, Ciprofloxacin, Cefotaxime, Pencillin G, and Amoxicillin.
From a geographical perspective, the global community acquired pneumonia market can be divided into North America, Europe, Asia Pacific, and the Rest of the World. The CAP markets in North America and Europe are currently leading the global market, owing to the highly developed medical infrastructure, the presence of favorable government regulations for treatment and reimbursement, and a high rate of awareness among individuals in these regions.
On the other hand, the Asia Pacific community acquired pneumonia market is expected to grow at the fastest rate in the coming years. This region is experiencing rapid growth in healthcare infrastructure, through which the medical industry can reach a large population pool that was previously inaccessible. At the same time, the number of people in the Asia Pacific region with higher disposable incomes and awareness of well-being is increasing, further contributing to the number of patients being treated every year. Adding to this momentum are the government grants and support present in various countries. This is especially true for South Korea, Japan, China, and India, as these nations are showing a sharp growth curve in the CAP market.
Full Research Report on Global Community Acquired Pneumonia Market: